Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Moat Score: 0/10 (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08329 Shenzhen Neptunus Interlong Bio-Technique Co Ltd HKSE:08329
48 GF Score
Price HK$0.10
GF Value HK$0.14
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Shenzhen Neptunus Interlong Bio-Technique Co Moat Score?

Shenzhen Neptunus Interlong Bio-Technique Co has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Shenzhen Neptunus Interlong Bio-Technique Co has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Shenzhen Neptunus Interlong Bio-Technique Co might have No Moat - No discernible moat.

Shenzhen Neptunus Interlong Bio-Technique Co  (HKSE:08329) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Shenzhen Neptunus Interlong Bio-Technique Co Moat Score Related Terms

HKSE:08329
48GF Score
Shenzhen Neptunus Interlong Bio-Technique Co Ltd HKSE:08329
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Overvalued in 2026?

Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co stock appears to be undervalued. The current stock price of HK$0.10 is trading 29.3% below its estimated GF Value™ of HK$0.14. GuruFocus considers Shenzhen Neptunus Interlong Bio-Technique Co to be Modestly Undervalued.

Key valuation signals for HKSE:08329:

  • Moat Score: 0
  • GF Value™: HK$0.14 vs. price of HK$0.10 (29.3% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the HKSE:08329 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shenzhen Neptunus Interlong Bio-Technique Co Business Description

Address 979 King’s Road, 43rd Floor, One Taikoo Place, Quarry Bay, Hong Kong, HKG
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sale of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines and medical devices; and the Sales and distribution of medicines, healthcare products, and medical devices.. The majority of revenue is generated from the Manufacturing and selling of medicines and medical devices segment.
48GF Score

Get the complete analysis for HKSE:08329

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.10
Price
HK$0.14
GF Value